Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest news about BridgeBio Pharma aggregated by PharmaCompass.com.

    Client Virtual Booth

    BRIDGEBIO PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    BridgeBio Pharma
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    421 Kipling Street, Palo Alto, CA 94301
    Telephone
    Telephone
    650-391-9740
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://bridgebio.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/bridgebio
    Twitter
    Twitter
    https://twitter.com/hashtag/bridgebio

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    https://www.globenewswire.com/news-release/2024/07/05/2909197/0/en/BridgeBio-Pharma-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    05 Jul 2024
    Share Share
    BridgeBio Receives FDA Designation For BBP-418 In LGMD2I/R9
    BridgeBio Receives FDA Designation For BBP-418 In LGMD2I/R9

    https://www.globenewswire.com/news-release/2024/06/18/2900308/0/en/BridgeBio-Pharma-Surpasses-Interim-Analysis-Enrollment-Target-and-Receives-U-S-FDA-Rare-Pediatric-Disease-Designation-for-BBP-418-a-Potential-Treatment-for-Limb-girdle-Muscular-Dys.html

    GLOBENEWSWIRE
    18 Jun 2024
    Share Share
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    https://www.globenewswire.com/news-release/2024/06/10/2895896/0/en/BridgeBio-Pharma-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    10 Jun 2024
    Share Share
    BridgeBio Doses First KRASG12C NSCLC Patient With BBO-8520 In ONKORAS Trial
    BridgeBio Doses First KRASG12C NSCLC Patient With BBO-8520 In ONKORAS Trial

    https://www.businesswire.com/news/home/20240606977682/en

    BUSINESSWIRE
    06 Jun 2024
    Share Share
    BridgeBio To Participate In Goldman Healthcare Conference
    BridgeBio To Participate In Goldman Healthcare Conference

    https://www.globenewswire.com/news-release/2024/06/06/2894570/0/en/BridgeBio-Pharma-to-Participate-in-the-45th-Annual-Goldman-Sachs-Global-Healthcare-Conference.html

    GLOBENEWSWIRE
    06 Jun 2024
    Share Share
    BridgeBio data show sustained benefit for achondroplasia drug
    BridgeBio data show sustained benefit for achondroplasia drug

    https://www.biopharmadive.com/news/bridgebio-infigratinib-achondroplasia-propel-study-results/717914/

    Ned Pagliarulo BIOPHARMADIVE
    05 Jun 2024
    Share Share
    BridgeBio: Durable Infigratinib Results In Achondroplasia Study
    BridgeBio: Durable Infigratinib Results In Achondroplasia Study

    https://www.globenewswire.com/news-release/2024/06/04/2892934/0/en/BridgeBio-Announces-Durable-Month-12-and-18-Phase-2-Cohort-5-Results-of-Oral-Infigratinib-in-Achondroplasia-and-First-Participant-Consented-in-ACCEL-for-Hypochondroplasia.html

    GLOBENEWSWIRE
    04 Jun 2024
    Share Share
    BridgeBio To Host Infigratinib Achondroplasia Phase 2 Data Call
    BridgeBio To Host Infigratinib Achondroplasia Phase 2 Data Call

    https://www.globenewswire.com/news-release/2024/06/03/2892563/0/en/BridgeBio-to-Host-Call-on-Month-12-and-18-Phase-2-Cohort-5-Results-of-Oral-Infigratinib-in-Achondroplasia-on-June-4-2024.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share
    BridgeBio touts additional ATTR-CM drug data in new analyses of Phase 3 trial
    BridgeBio touts additional ATTR-CM drug data in new analyses of Phase 3 trial

    https://endpts.com/bridgebio-touts-additional-attr-cm-drug-data-in-new-analyses-of-phase-3-trial/

    Katherine Lewin ENDPTS
    29 May 2024
    Share Share
    Acoramidis Increases Transthyretin Tied To Better Cardiac Outcomes In ATTR-CM
    Acoramidis Increases Transthyretin Tied To Better Cardiac Outcomes In ATTR-CM

    https://www.globenewswire.com/news-release/2024/05/29/2890251/0/en/Additional-Data-Showing-Acoramidis-Increases-Serum-Transthyretin-Which-is-Associated-with-Improved-Cardiovascular-Outcomes-Presented-at-ISA-from-BridgeBio-Pharma-s-Phase-3-ATTRibut.html

    GLOBENEWSWIRE
    29 May 2024
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    famar-2024-07-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search